WASHINGTON, May 10, 2023 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today responded to the ruling in its Hetlioz® Abbreviated New Drug Application appeal. Today a three-judge panel of the United States Court of Appeals for the Federal Circuit issued a written…